Inflammatory Proteins,Gene Polymorphisms, and Transcriptome Profiles in Patients With Chronic Atrophic Acrodermatitis
Overview
- Phase
- Not Applicable
- Intervention
- doxycycline orally, 100 mg, bid, 14 days
- Conditions
- Chronic Atrophic Acrodermatitis
- Sponsor
- University Medical Centre Ljubljana
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- inflammatory proteins in patients with chronic atrophic dermatitis
- Last Updated
- 8 years ago
Overview
Brief Summary
The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with chronic atrophic dermatitis to gain better insight into pathogenesis of chronic infection with Borrelia burgdorferi sensu lato.
Investigators
Franc Strle
M.D., PhD
University Medical Centre Ljubljana
Eligibility Criteria
Inclusion Criteria
- •chronic atrophic dermatitis in patients \>18 years
Exclusion Criteria
- Not provided
Arms & Interventions
ACA-doxy 14 days
patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days
Intervention: doxycycline orally, 100 mg, bid, 14 days
ACA-doxy 28 days
patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days
Intervention: doxycycline orally, 100 mg, bid, 28 days
Outcomes
Primary Outcomes
inflammatory proteins in patients with chronic atrophic dermatitis
Time Frame: up to 24 months
The inflammatory immune profiles will be assessed using Luminex to measure the expression of cytokines and chemokines representative of innate and adaptive TH1, TH2, TH17, and B cell responses.
Secondary Outcomes
- clinical characteristics of patients with chronic atrophic dermatitis treated with doxycycline for 14 or 28 days(at enrollment, at 2, 6 12 and 24 months follow-up)